Wells Fargo & Company Verve Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 34,939 shares of VERV stock, worth $195,658. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,939
Previous 26,983
29.49%
Holding current value
$195,658
Previous $358,000
52.51%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding VERV
# of Institutions
174Shares Held
74.8MCall Options Held
115KPut Options Held
144K-
Alphabet Inc. Mountain View, CA12.3MShares$69.2 Million3.79% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$37.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$29.5 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.53MShares$25.4 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.87MShares$21.7 Million0.01% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $336M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...